Comparing the clinical utility and diagnostic performance of cerebrospinal fluid P-tau181, P-tau217 and P-tau231 assays

Antoine Leuzy, Shorena Janelidze, Niklas Mattsson-Carlgren, Sebastian Palmqvist, Dirk Jacobs, Claudia Cicognola, Erik Stomrud, Oskar Hansson, Eugeen Vanmechelen & Jeffrey Dage
Background and Objectives: Phosphorylated tau (P-tau) in cerebrospinal fluid (CSF) is considered an important biomarker in Alzheimer’s disease (AD) and has been incorporated in recent diagnostic criteria. Several variants exist, including P-tau at threonines 181 (P-tau181), 217 (P-tau217) and 231 (P-tau231). However, no studies have compared their diagnostic performance or association to amyloid-β (Aβ) and Tau positron emission tomography (PET). Understanding which P-tau variant to use remains an important yet answered question. We aimed to...
23 views reported since publication in 2021.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?
6 downloads reported since publication in 2021.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?